MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2018 International Congress

    Frequency of the LRRK2 and GBA mutations in Russian population with Parkinson’s disease

    K. Senkevich, A. Emelyanov, M. Nikolaev, T. Usenko, A. Bezrukova, I. Miliukhina, A. Kopytova, A. Timofeeva, A. Yakimovsky, S. Pchelina (Saint-Petersburg, Russian Federation)

    Objective: To estimate the frequency of LRRK2 mutation (G2019S) and GBA mutations (N370S, L444P) and polymorphic variants (E326K, T369M) in PD and controls in the…
  • 2018 International Congress

    Levels of plasma alpha-synuclein as measured using Single Molecule Array technology is higher in Parkinson’s disease compared to controls and is not influenced by LRRK2 genotype

    YJ. Tan, A. Ng, ZH. Lu, S. Ng, E. Ng, F. Setiawan, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

    Objective: To investigate plasma alpha-synuclein levels in PD using ultra-sensitive protein detection technology, and to determine the association of plasma alpha-synuclein with cognitive, motor and…
  • 2018 International Congress

    Delivery of AAV alpha synuclein to a mouse and rat provides a useful model for the assessment of anti-parkinsonian efficacy of chronic inhibition of LRRK2

    R. Hodgson, T. Parkkari, T. Martinez, M. Fell, D. Bryce, T. Heikkinen, A. Nurmi, T. Bragge, M. Taavitsainen, T. Lanz, M. Baptista (Wilmington, MA, USA)

    Objective: 1. To create an in vivo model system to be used to assess the effect of chronically inhibiting LRRK2 pharmacologically. 2. To confirm previous…
  • 2018 International Congress

    Study on feasibility to develop a central nervous system (CNS) Leucine-rich repeat kinase 2 (LRRK2) PET tracer

    Z. Zeng, P. Miller, T. Graham, L. Tong, D. Hesk, W. Li, E. Hostetler (West Point, PA, USA)

    Objective: To assess feasibility of developing a CNS LRRK2 PET tracer. Background: LRRK2 enzyme belongs to the leucine-rich repeat kinase family. Pathogenic mutations in the…
  • 2018 International Congress

    Effect of deep brain stimulation on clinical outcome in Parkinson’s disease patients with different genetic status

    M. Kestenbaum, R. Schvartz, Y. Balash, A. Hilel, A. Mirelman, N. Giladi, T. Gurevich (Tel Aviv, Israel)

    Objective: The aim of this study was to evaluate the effect of the genetic status on the clinical outcome of PD patients undergoing DBS. Background:…
  • 2018 International Congress

    Classifying carriers of the G2019S mutation in the LRRK2 gene using MRI radiomics analysis

    M. Artzi, A. Thaler, A. Orr Urterger, T. Hendler, M. Sela, A. Mirelman, D. Ben Bashat (Tel Aviv, Israel)

    Objective: To use radiomics approach based on conventional MRI to classify carriers of LRRK2 mutation among non-manifesting first degree relatives of patients with PD. Background:…
  • 2018 International Congress

    Clinical phenotype analysis of Parkinson’s disease associated with LRRK2 variants in Chinese Han population

    C. Gu, K. Li, J. Zhang, H. Jin, Y. Ge, C. Liu (Suzhou, China)

    Objective: Our study aimed to compare motor and non-motor symptoms, imaging features and molecular markers of patients with Parkinson’s disease (PD) who are carriers of…
  • 2018 International Congress

    Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson’s disease patients with the LRRK2 mutation?

    C. Carricarte Naranjo, C. Marras, N. Visanji, D. Cornforth, L. Sanchez-Rodriguez, B. Schuele, S. Goldman, M. Estévez Báez, P. Stein, A. Lang, H. Jelinek, A. Machado García (Havana, Cuba)

    Objective: Assessment of cardiac autonomic function through standard and novel features of heart rate variability (HRV) in individuals who carry the G2019S mutation in the…
  • 2018 International Congress

    Evaluation of the relationship between Leucine-rich repeat kinase 2 (LRRK2) S1647T variants and smoking with risk of Parkinson’s Disease in the Singapore population

    ZH. Lu, S. Ng, X.X. Huang, E. Ng, M. Parimelalagan, F. Setiawan, L. Tan, W.L. Au, K.Y. Tay, ZY. Xu, K. Prakash, E.K. Tan (Singapore)

    Objective: To investigate whether cigarette smoking influences the relationship between S1647T variants and risk of PD in the Singapore population. Background: Case-control studies in southern…
  • 2018 International Congress

    Objective and quantifiable assessment of sleep in patients with Parkinson’s disease using a wearable sensor

    A. Mirelman, I. Hilell, N. Omer, A. Thaler, M. Kestenbaum, O. Assais, A. Orr-Urtreger, M. Brys, J. Cedarbaum, J. Hausdorff, N. Giladi (Tel Aviv, Israel)

    Objective: To explore the feasibility of using a body-fixed sensor (BFS) to assess sleep disturbances in patients with Parkinson's disease (PD), carriers and non-carriers of…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley